Showing results (181-190 of 238) with videos related to

Sort By:
Pageof 24
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 28, 2021
Current directions in tau research: Highlights from Tau 2020Claire Sexton, Heather Snyder, Dirk Beher, et al.
Medrxiv : the Preprint Server for Health Sciences|July 17, 2025
Rare but Relevant: Assessing Variants in Dystonia-linked Genes in Parkinson's DiseaseLara M Lange, Zih-Hua Fang, Laurel Screven, et al.
Annals of Neurology|April 26, 2021
Investigation of Autosomal Genetic Sex Differences in Parkinson's DiseaseCornelis Blauwendraat, Hirotaka Iwaki, Mary B Makarious, et al.
The Lancet. Neurology|June 20, 2025
Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort studyChristina D Orrú, David P Vaughan, Nirosen Vijiaratnam, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|March 19, 2019
How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsyMax-Joseph Grimm, Gesine Respondek, Maria Stamelou, et al.
Medrxiv : the Preprint Server for Health Sciences|January 13, 2025
African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1Pilar Álvarez Jerez, Peter A Wild Crea, Daniel M Ramos, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 11, 2025
Rare but Relevant? Assessing Variants in Dystonia-Linked Genes in Parkinson's DiseaseLara M Lange, Zih-Hua Fang, Laurel Screven, et al.
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
A pathogenic variant in RAB32 causes autosomal dominant Parkinson's disease and activates LRRK2 kinaseEmil K Gustavsson, Jordan Follett, Joanne Trinh, et al.
The Lancet. Neurology|April 13, 2024
RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analysesEmil K Gustavsson, Jordan Follett, Joanne Trinh, et al.
Nature Medicine|March 25, 2026
LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trialOmar S Mabrouk, Ben Tichler, H Moore Arnold, et al.
Pageof 24